Episodes

Wednesday Jan 17, 2024
Wednesday Jan 17, 2024
AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will China approve the deal? And e-commerce company East Buy's CEO gets sacked under pressure from its top online salesman. How much power do such influencers wield at Chinese internet companies?

Tuesday Jan 09, 2024
Tuesday Jan 09, 2024
China's big national banks are growing wary of their smaller regional counterparts. Will this put further pressure on the smaller lenders, many of which are already struggling? And two leading bubble tea makers file for Hong Kong IPOs. Will investors scoop up their shares, or shun them over concerns about China's slowing economy?

Tuesday Jan 02, 2024
Tuesday Jan 02, 2024
China is raising the bar for its vast field of venture capital and private equity companies, a move that looks aimed at avoiding a repeat of the P2P crisis a few years back. What's the implication for Chinese startups? And former autonomous trucking highflier TuSimple is retreating from the U.S. to focus on its China business. What's driving this abrupt turnaround for a company that was once so promising?

Thursday Dec 21, 2023
Thursday Dec 21, 2023
Chinese leaders said they'll prioritize progress and stability in 2024 at their annual Central Economic Work Conference. Does that mean they'll put greater emphasis on the economy? And France and Turkey take new steps that could limit Chinese EV imports. What's behind this growing bias against Chinese electric cars that are flooding the global market?

Monday Dec 04, 2023
Monday Dec 04, 2023
EV maker Zeekr, owned by car giant Geely, has filed for a New York IPO to raise as much as $1 billion. But with only two years of history, will investors embrace the company? And bubble tea giant Mixue Bingcheng eyes its own listing in Hong Kong. But will investors worry that China's premium tea market is overheated and about to burst?

Tuesday Nov 28, 2023
Tuesday Nov 28, 2023
After falling to multiyear lows, China's yuan has come roaring back in recent weeks. But what has changed, and are the gains for real? And China approves the $69 billion merger of VMWare with global chip giant Broadcom after more than a year. Does this signal a friendlier new approach by China to global chip M&A?

Monday Nov 06, 2023
Monday Nov 06, 2023
After several years of unbridled enthusiasm, investors have sharply pulled back their support for Chinese healthcare startups. Why the sudden cold feet toward this group? And a decade after acquiring U.S. pork giant Smithfield, China's WH Group is eyeing a New York listing for the company. Could this be prelude to a sale of this pork barrel investment?

Tuesday Oct 31, 2023
Tuesday Oct 31, 2023
A summit between Xi Jinping and Joe Biden is looking increasingly likely after China’s foreign minister traveled to Washington last week. But will such a meeting accomplish anything? And Stellantis, owner of the Chrysler and Peugeot brands, will pay $1 billion for 20% of Chinese EV maker Leapmotor. What’s driving this odd partnership between a global giant and a struggling startup?

Monday Oct 16, 2023
Monday Oct 16, 2023
Ford has put the brakes on a battery plant being built for it in the U.S. by China’s CATL. Is this the end of the road for Chinese EV investments in the U.S.? And pet community operator Boqii is leaving the NYSE after a “ruff” three years. Are more Chinese companies likely to follow Boqii’s lead?

Monday Oct 09, 2023
Monday Oct 09, 2023
China has barred a top executive from U.S. risk control firm Kroll from leaving the country. Will this send more chills through foreign companies in China? And after implementing a strict new law on cross-border data transfers, China rolls out a new draft rule rolling back some of the toughest requirements. Will that be enough to ease concerns of jittery foreign companies?